117 related articles for article (PubMed ID: 10068364)
21. Linezolid resistance in a clinical isolate of Staphylococcus aureus.
Tsiodras S; Gold HS; Sakoulas G; Eliopoulos GM; Wennersten C; Venkataraman L; Moellering RC; Ferraro MJ
Lancet; 2001 Jul; 358(9277):207-8. PubMed ID: 11476839
[TBL] [Abstract][Full Text] [Related]
22. Linezolid.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):815-27; discussion 828. PubMed ID: 10804037
[TBL] [Abstract][Full Text] [Related]
23. In vitro activities of five new antimicrobial agents against Brucella melitensis.
Trujillano-Martín I; García-Sánchez E; Fresnadillo MJ; García-Sánchez JE; García-Rodríguez JA; Montes Martínez I
Int J Antimicrob Agents; 1999 Jul; 12(2):185-6. PubMed ID: 10418765
[No Abstract] [Full Text] [Related]
24. The in-vitro activity of linezolid (U-100766) and tentative breakpoints.
Wise R; Andrews JM; Boswell FJ; Ashby JP
J Antimicrob Chemother; 1998 Dec; 42(6):721-8. PubMed ID: 10052894
[TBL] [Abstract][Full Text] [Related]
25. Oxazolidinone antibiotics.
Diekema DJ; Jones RN
Lancet; 2001 Dec; 358(9297):1975-82. PubMed ID: 11747939
[TBL] [Abstract][Full Text] [Related]
26. Linezolid: an oxazolidinone antimicrobial agent.
Paladino JA
Am J Health Syst Pharm; 2002 Dec; 59(24):2413-25. PubMed ID: 12503340
[TBL] [Abstract][Full Text] [Related]
27. Novel tetrahydro-thieno pyridyl oxazolidinone: an antibacterial agent.
Lohray BB; Lohray VB; Srivastava BK; Kapadnis PB; Pandya P
Bioorg Med Chem; 2004 Sep; 12(17):4557-64. PubMed ID: 15358283
[TBL] [Abstract][Full Text] [Related]
28. In vitro antimicrobial activity of the novel oxazolidinone tedizolid and comparator agents against Staphylococcus aureus and linezolid-resistant Gram-positive pathogens: a multicentre study in China.
Chen H; Yang Q; Zhang R; He W; Ma X; Zhang J; Xia F; Zhao F; Cao J; Liu Y; Wu W; Hu D; Wang Q; Zhao C; Zhang F; Wang X; Wang Z; Li H; Wang H
Int J Antimicrob Agents; 2014 Sep; 44(3):276-7. PubMed ID: 25108879
[No Abstract] [Full Text] [Related]
29. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.
Gonzales RD; Schreckenberger PC; Graham MB; Kelkar S; DenBesten K; Quinn JP
Lancet; 2001 Apr; 357(9263):1179. PubMed ID: 11323048
[TBL] [Abstract][Full Text] [Related]
30. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors.
Fines M; Leclercq R
J Antimicrob Chemother; 2000 Jun; 45(6):797-802. PubMed ID: 10837432
[TBL] [Abstract][Full Text] [Related]
31. Preface. The evidence for the clinical role of linezolid beyond its licence.
Koerner R; Hope R
J Antimicrob Chemother; 2011 May; 66 Suppl 4():iv1. PubMed ID: 21553405
[No Abstract] [Full Text] [Related]
32. Preserving the effectiveness of antibiotics.
Gaynes RP
JAMA; 2010 Jun; 303(22):2293-4. PubMed ID: 20530785
[No Abstract] [Full Text] [Related]
33. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
[TBL] [Abstract][Full Text] [Related]
34. Linezolid.
French G
Int J Clin Pract; 2001; 55(1):59-63. PubMed ID: 11219321
[TBL] [Abstract][Full Text] [Related]
35. Tedizolid: a novel oxazolidinone for Gram-positive infections.
Moellering RC
Clin Infect Dis; 2014 Jan; 58 Suppl 1():S1-3. PubMed ID: 24343826
[No Abstract] [Full Text] [Related]
36. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam.
Sisson TL; Jungbluth GL; Hopkins NK
J Clin Pharmacol; 1999 Dec; 39(12):1277-82. PubMed ID: 10586394
[TBL] [Abstract][Full Text] [Related]
37. Linezolid for the treatment of resistant gram-positive cocci.
Bain KT; Wittbrodt ET
Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064
[TBL] [Abstract][Full Text] [Related]
38. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.
Seedat J; Zick G; Klare I; Konstabel C; Weiler N; Sahly H
Antimicrob Agents Chemother; 2006 Dec; 50(12):4217-9. PubMed ID: 16982791
[TBL] [Abstract][Full Text] [Related]
39. Linezolid.
Narang M; Gomber S
Indian Pediatr; 2004 Nov; 41(11):1129-32. PubMed ID: 15591662
[TBL] [Abstract][Full Text] [Related]
40. What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.
Gleckman R
Postgrad Med; 2001 Mar; 109(3):87-91; quiz 28. PubMed ID: 11265366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
